Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

Volker Herrmann, M.D., has also stepped away from the helm, with Sonata chairman David Khougazian taking the wheel as acting ...

“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...

After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...